RARITAN, N.J., June 28 /PRNewswire/ —
Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the
signing of a five-year collaboration agreement with the David H.
Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology.
Called TRANSCEND, the collaboration agreement will foster
oncology research and technology development in the areas of cancer
diagnostics, cancer biology pre-malignancies, genetic models of
disease, and profiles of the tumor microenvironment.
“The TRANSCEND program embodies our external innovation approach
to research,” said William N. Hait,
M.D., Ph.D., Global Therapeutic Area Head, Oncology, for Johnson
& Johnson Pharmaceutical Research & Development, L.L.C., an
affiliate of Ortho-McNeil Janssen.
“By collaborating with leading academic institutions and
colleagues at the interface of engineering and biology, we’re able
to bring together the best scientific minds in industry and
academia to meet unmet medical needs in patients with cancer.”
A Joint Scientific Steering Committee composed of MIT faculty members and Ortho-McNeil Janssen employees will
jointly review and select proposals from MIT researchers for funding. Projects
will involve interdisciplinary faculty, students and staff to
address oncology solutions. In addition, there is the
potential for visiting scientists from Ortho-McNeil Janssen to participate in
projects within the investigators’ laboratories at the Koch
Institute.
“The visiting scientist aspect of the program is designed to
promote interactive exchange between our organizations
‘/>”/>
